β_1受体基因和药物代谢酶CYP2D6*10与高血压病基因导向治疗的相关性研究  

Research progression for influence of β_1 receptor gene and CYP2D6*10 enzyme polymorphism in geneoriented treatment of hypertension

作　　者：张峰[1] 杨军[1] 李莉[2] 

机构地区：[1]佳木斯大学附属第一医院心内科,黑龙江佳木斯市154002 [2]北京市垂杨柳医院心内科

出　　处：《心血管康复医学杂志》2013年第6期629-631,共3页Chinese Journal of Cardiovascular Rehabilitation Medicine

摘　　要：随着基因治疗学研究不断深入,高血压病治疗也开始由传统给药模式转向基因导向治疗的新模式。由于原发性高血压病的发病与遗传易感基因多态性有关,且基因分布存在种族及个体差异,导致药物疗效亦存在个体差异。本文对β_1受体基因(β_1-AR)和药物代谢酶CYP2D6*10的遗传多态性在美托洛尔"基因导向型个体化"降压治疗中影响的研究进展作一综述。Along with gene therapy research continues developing, hypertension treatment starts turning into new mode of gene-oriented treatment from traditional administration mode. Because occurrence of essential hypertension is related to genetic predisposing gene polymorphism, and genetic distribution varies among races and individuals, leading to individual difference of drug therapeutic effect. The present article made an overview about research progression for influence of genetic polymorphisms of β1 receptor gene （β1 - AR） and CYP2D6 ＊ 10 enzyme in ＂gene - oriented individualization＂ lowering blood pressure treatment of metoprolol.

关 键 词：高血压 受体 肾上腺素能Β1 基因 

分 类 号：R544.109[医药卫生—心血管疾病]